| 6.47 -0.43 (-6.23%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.51 |
1-year : | 10.72 |
| Resists | First : | 8.14 |
Second : | 9.18 |
| Pivot price | 7.21 |
|||
| Supports | First : | 6.46 |
Second : | 5.37 |
| MAs | MA(5) : | 6.77 |
MA(20) : | 7.4 |
| MA(100) : | 6.78 |
MA(250) : | 4.34 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 15.2 |
D(3) : | 16.7 |
| RSI | RSI(14): 32.1 |
|||
| 52-week | High : | 11.88 | Low : | 1.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CCCC ] has closed above bottom band by 10.0%. Bollinger Bands are 43.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7 - 7.04 | 7.04 - 7.07 |
| Low: | 6.38 - 6.42 | 6.42 - 6.45 |
| Close: | 6.41 - 6.47 | 6.47 - 6.53 |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Sun, 14 Apr 2024
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Thu, 11 Apr 2024
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 73.0% in March - MarketBeat
Tue, 19 Mar 2024
C4 Therapeutics Inc (CCCC) has fallen -18.87% in a Week, Should You Hold? - InvestorsObserver
Thu, 29 Feb 2024
Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts - Simply Wall St
Sat, 24 Feb 2024
C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Simply Wall St
Thu, 22 Feb 2024
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 69 (M) |
| Held by Insiders | 5.25e+007 (%) |
| Held by Institutions | 11.6 (%) |
| Shares Short | 2,970 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3715e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 147.7 % |
| Return on Equity (ttm) | -21.6 % |
| Qtrly Rev. Growth | 2.076e+007 % |
| Gross Profit (p.s.) | 4.48 |
| Sales Per Share | -15.52 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -107 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.2 |
| Price to Book value | 0 |
| Price to Sales | -0.42 |
| Price to Cash Flow | 5.07 |
| Dividend | 0 |
| Forward Dividend | 9.15e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|